CO2017002494A2 - N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b - Google Patents
N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2bInfo
- Publication number
- CO2017002494A2 CO2017002494A2 CONC2017/0002494A CO2017002494A CO2017002494A2 CO 2017002494 A2 CO2017002494 A2 CO 2017002494A2 CO 2017002494 A CO2017002494 A CO 2017002494A CO 2017002494 A2 CO2017002494 A2 CO 2017002494A2
- Authority
- CO
- Colombia
- Prior art keywords
- oxaryl
- nr2b
- alkylaryl
- negative allosteric
- allosteric modulators
- Prior art date
Links
- 229940126662 negative allosteric modulator Drugs 0.000 title abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000034527 Retinoid X Receptors Human genes 0.000 abstract 1
- 108010038912 Retinoid X Receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente invención se refiere a un modulador alostérico negativo de Nalquiarilo-5-oxiarilo-octadihidrociclopentano[c]pirrol para receptores NR2B, los cuales son importantes en el tratamiento de enfermedades neurológicas y tienen la siguiente formula: Dónde R1, R2, L1, L2, X, Y y Y’ están descritos en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462056284P | 2014-09-26 | 2014-09-26 | |
| PCT/US2015/051694 WO2016049165A1 (en) | 2014-09-26 | 2015-09-23 | N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017002494A2 true CO2017002494A2 (es) | 2017-08-31 |
Family
ID=55581945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0002494A CO2017002494A2 (es) | 2014-09-26 | 2017-03-15 | N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b |
Country Status (40)
| Country | Link |
|---|---|
| US (4) | US10239835B2 (es) |
| EP (4) | EP3197868B1 (es) |
| JP (4) | JP6473227B2 (es) |
| KR (1) | KR102479356B1 (es) |
| CN (1) | CN106795111B (es) |
| AP (1) | AP2017009832A0 (es) |
| AR (1) | AR103199A1 (es) |
| AU (1) | AU2015320721B2 (es) |
| BR (1) | BR112017006093B1 (es) |
| CA (1) | CA2962569C (es) |
| CL (1) | CL2017000474A1 (es) |
| CO (1) | CO2017002494A2 (es) |
| CR (1) | CR20170114A (es) |
| CU (1) | CU24482B1 (es) |
| CY (1) | CY1123533T1 (es) |
| DK (1) | DK3197868T3 (es) |
| EA (1) | EA034937B1 (es) |
| EC (1) | ECSP17025302A (es) |
| ES (3) | ES2956546T3 (es) |
| GT (1) | GT201700062A (es) |
| HR (1) | HRP20200959T1 (es) |
| HU (1) | HUE049698T2 (es) |
| IL (1) | IL250909B (es) |
| JO (1) | JO3579B1 (es) |
| LT (1) | LT3197868T (es) |
| MX (1) | MX2017003940A (es) |
| MY (1) | MY182342A (es) |
| NZ (1) | NZ729569A (es) |
| PE (1) | PE20170893A1 (es) |
| PH (1) | PH12017500513A1 (es) |
| PL (1) | PL3197868T3 (es) |
| PT (1) | PT3197868T (es) |
| RS (1) | RS60497B1 (es) |
| SG (1) | SG11201702023QA (es) |
| SI (1) | SI3197868T1 (es) |
| TN (1) | TN2017000076A1 (es) |
| TW (1) | TWI687407B (es) |
| UY (1) | UY36326A (es) |
| WO (1) | WO2016049165A1 (es) |
| ZA (1) | ZA201701061B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| WO2019089676A1 (en) | 2017-10-31 | 2019-05-09 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| WO2019152809A1 (en) | 2018-02-02 | 2019-08-08 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor m4 |
| CN113950478B (zh) * | 2019-06-04 | 2024-02-02 | 勃林格殷格翰国际有限公司 | 作为nr2b负向调节剂的嘌呤衍生物及其作为药物的用途，特别是用于治疗抑郁病症 |
| CN111481543A (zh) * | 2020-05-21 | 2020-08-04 | 苏州健雄职业技术学院 | Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途 |
| AU2021390209A1 (en) | 2020-12-04 | 2023-06-22 | Novartis Ag | Dosage regimen for a nr2b-nmda receptor nam for the treatment of depression |
| JP2021058765A (ja) * | 2021-01-19 | 2021-04-15 | 株式会社藤商事 | 遊技機 |
| EP4313041A1 (en) * | 2021-03-26 | 2024-02-07 | Novartis AG | Novel cyclopental[c]pyrrol negative allosteric modulators of nr2b |
| CN117120053A (zh) * | 2021-03-26 | 2023-11-24 | 诺华股份有限公司 | 新的环戊二烯并[c]吡咯NR2B负变构调节剂 |
| WO2023233357A1 (en) | 2022-06-02 | 2023-12-07 | Novartis Ag | Subcutaneous administration of onfasprodil and dosing methods for use in the treatment of depression disorders |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532243A (en) | 1992-02-14 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Antipsychotic nitrogen-containing bicyclic compounds |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| DE4341403A1 (de) * | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| US5726172A (en) * | 1996-01-16 | 1998-03-10 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| US6369076B1 (en) * | 1999-10-29 | 2002-04-09 | Merck & Co. Inc. | 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
| AU2005219438B2 (en) | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| DK1761542T3 (da) | 2004-06-09 | 2008-04-28 | Hoffmann La Roche | Octahydropyrrolo[3,4-C] pyrrolderivater og anvendelsen deraf som antivirusmidler |
| WO2006012396A1 (en) | 2004-07-22 | 2006-02-02 | Glaxo Group Limited | Antibacterial agents |
| HUP0401523A3 (en) | 2004-07-29 | 2007-05-02 | Richter Gedeon Vegyeszet | Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them |
| EP1874318A2 (en) | 2005-04-19 | 2008-01-09 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| WO2007128458A1 (en) | 2006-04-28 | 2007-11-15 | Laboratorios Del Dr. Esteve, S.A. | Bicyclic tetrahydropyrrole compounds |
| EP1849772A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios Del Dr. Esteve, S.A. | Bicyclic tetrahydropyrrole compounds |
| TW200845977A (en) | 2007-03-30 | 2008-12-01 | Targacept Inc | Sub-type selective azabicycloalkane derivatives |
| US8907095B2 (en) | 2007-10-22 | 2014-12-09 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119 |
| JP5438028B2 (ja) | 2008-01-23 | 2014-03-12 | ジエンス ハンセン ファーマセウティカル カンパニー リミテッド | アザビシクロオクタンの誘導体、その製造方法及びそのジペプチジルペプチダーゼｉｖの阻害剤としての用途 |
| US8211933B2 (en) | 2008-12-12 | 2012-07-03 | Vanderbilt University | 3.3.0 bicyclic GlyT1 inhibitors and methods of making and using same |
| FR2945534B1 (fr) * | 2009-05-12 | 2012-11-16 | Sanofi Aventis | DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| FR2945533B1 (fr) * | 2009-05-12 | 2011-05-27 | Sanofi Aventis | Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| WO2011085170A1 (en) | 2010-01-07 | 2011-07-14 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| WO2011149993A2 (en) | 2010-05-25 | 2011-12-01 | Abbott Laboratories | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS |
| CN102432598A (zh) * | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | 三环化合物、其制备方法及其在医药上的应用 |
| US8501768B2 (en) | 2011-05-17 | 2013-08-06 | Hoffmann-La Roche Inc. | Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| ES2682755T3 (es) | 2011-12-21 | 2018-09-21 | Jiangsu Hengrui Medicine Co. Ltd. | Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales |
| UA116547C2 (uk) | 2012-09-25 | 2018-04-10 | Ф. Хоффманн-Ля Рош Аг | Біциклічні похідні |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| US9418332B2 (en) | 2013-08-16 | 2016-08-16 | Qualcomm Incorporated | Post ghost plasticity |
| WO2015048507A1 (en) * | 2013-09-26 | 2015-04-02 | Mnemosyne Pharmaceuticals, Inc. | Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b |
| PE20161134A1 (es) | 2014-03-26 | 2016-10-29 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| JO3579B1 (ar) * | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
-
2015
- 2015-09-22 JO JOP/2015/0237A patent/JO3579B1/ar active
- 2015-09-23 LT LTEP15844057.8T patent/LT3197868T/lt unknown
- 2015-09-23 BR BR112017006093-0A patent/BR112017006093B1/pt active IP Right Grant
- 2015-09-23 EP EP15844057.8A patent/EP3197868B1/en active Active
- 2015-09-23 ES ES21202255T patent/ES2956546T3/es active Active
- 2015-09-23 WO PCT/US2015/051694 patent/WO2016049165A1/en active Application Filing
- 2015-09-23 PE PE2017000506A patent/PE20170893A1/es unknown
- 2015-09-23 CN CN201580051671.3A patent/CN106795111B/zh active Active
- 2015-09-23 EP EP20159713.5A patent/EP3683207B1/en active Active
- 2015-09-23 CA CA2962569A patent/CA2962569C/en active Active
- 2015-09-23 MX MX2017003940A patent/MX2017003940A/es active IP Right Grant
- 2015-09-23 SG SG11201702023QA patent/SG11201702023QA/en unknown
- 2015-09-23 EP EP23185898.6A patent/EP4282412A3/en active Pending
- 2015-09-23 MY MYPI2017700652A patent/MY182342A/en unknown
- 2015-09-23 NZ NZ729569A patent/NZ729569A/en unknown
- 2015-09-23 HU HUE15844057A patent/HUE049698T2/hu unknown
- 2015-09-23 JP JP2017516358A patent/JP6473227B2/ja active Active
- 2015-09-23 KR KR1020177007813A patent/KR102479356B1/ko active IP Right Grant
- 2015-09-23 DK DK15844057.8T patent/DK3197868T3/da active
- 2015-09-23 PT PT158440578T patent/PT3197868T/pt unknown
- 2015-09-23 ES ES20159713T patent/ES2911004T3/es active Active
- 2015-09-23 EA EA201790713A patent/EA034937B1/ru not_active IP Right Cessation
- 2015-09-23 AP AP2017009832A patent/AP2017009832A0/en unknown
- 2015-09-23 PL PL15844057T patent/PL3197868T3/pl unknown
- 2015-09-23 TN TN2017000076A patent/TN2017000076A1/en unknown
- 2015-09-23 EP EP21202255.2A patent/EP3974420B1/en active Active
- 2015-09-23 RS RS20200721A patent/RS60497B1/sr unknown
- 2015-09-23 SI SI201531255T patent/SI3197868T1/sl unknown
- 2015-09-23 CR CR20170114A patent/CR20170114A/es unknown
- 2015-09-23 CU CU2017000037A patent/CU24482B1/es unknown
- 2015-09-23 AU AU2015320721A patent/AU2015320721B2/en active Active
- 2015-09-23 US US15/506,592 patent/US10239835B2/en active Active
- 2015-09-23 ES ES15844057T patent/ES2791327T3/es active Active
- 2015-09-25 TW TW104131936A patent/TWI687407B/zh active
- 2015-09-25 UY UY0001036326A patent/UY36326A/es active IP Right Grant
- 2015-09-25 AR ARP150103084A patent/AR103199A1/es active IP Right Grant
-
2017
- 2017-02-13 ZA ZA2017/01061A patent/ZA201701061B/en unknown
- 2017-02-28 CL CL2017000474A patent/CL2017000474A1/es unknown
- 2017-03-02 IL IL250909A patent/IL250909B/en active IP Right Grant
- 2017-03-15 CO CONC2017/0002494A patent/CO2017002494A2/es unknown
- 2017-03-17 PH PH12017500513A patent/PH12017500513A1/en unknown
- 2017-03-24 GT GT201700062A patent/GT201700062A/es unknown
- 2017-04-24 EC ECIEPI201725302A patent/ECSP17025302A/es unknown
-
2019
- 2019-01-23 JP JP2019008873A patent/JP6772307B2/ja active Active
- 2019-01-23 US US16/255,500 patent/US10781174B2/en active Active
-
2020
- 2020-06-15 CY CY20201100542T patent/CY1123533T1/el unknown
- 2020-06-17 HR HRP20200959TT patent/HRP20200959T1/hr unknown
- 2020-08-12 US US16/991,684 patent/US20200369610A1/en not_active Abandoned
- 2020-09-30 JP JP2020166129A patent/JP7216060B2/ja active Active
-
2022
- 2022-05-03 US US17/735,386 patent/US20220274925A1/en active Pending
-
2023
- 2023-01-19 JP JP2023006525A patent/JP2023052515A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017002494A2 (es) | N-alquilaril-5-oxiaril-octahidro ciclopenta[c]pirrol moduladores alostéricos negativos de nr2b | |
| CL2019000588A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tlr. | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
| CL2017002483A1 (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CR20160212A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| ECSP16061758A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
| CR20150571A (es) | Compuestos y composiciones terapéuticos | |
| ECSP14017269A (es) | Compuestos para tratar la atrofia muscular espinal | |
| PE20151788A1 (es) | Inhibidores de bromodominios tetraciclicos | |
| UY33497A (es) | Derivados de espiro-piperidina como moduladores s1p | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| GT201200004A (es) | Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria | |
| EA201590881A1 (ru) | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 | |
| CR20140476A (es) | Agentes para tratar transtornos que implican la modulación de receptores de rianodina | |
| CL2017000818A1 (es) | Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii | |
| SV2017005381A (es) | Compuestos de imidazopiridazina | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
| CL2019000274A1 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat). | |
| CL2017000312A1 (es) | Elección de microarn como diana para trastornos metabólicos | |
| DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| CL2019002583A1 (es) | Inhibidores duales de magl y faah. |